CrushSCI.com
Journal Selection & Manuscript Polishing Services
ANTIVIRAL RESEARCH journal cover Medicine
Back to journal directory

Review Cycle Records

ANTIVIRAL RESEARCH

Elsevier SCIE Non-OA
2026 Emerging Zone 22025 CAS Zone 22025 JCR Q1
119.1Average days
116Median days
26Fastest days
186Longest days
1832025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

93 days

High-yield production of immunogenic PV3 virus-like particle in yeast

AuthorsTian Chen; Qin Hong; Wenyu Han; Shuxia Wang; Cheng Lin; Jiaqi Yao; Chaoyang Lian; Qingwei Liu; Xiaoli Wang; Yanqiu Zhou; Yao Cong; Zhong Huang

AffiliationsShanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China; Key Laboratory of RNA Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China; Huasong (Shanghai) Biomedical Technology Co., LTD, Shanghai, China; Chongqing Huazhi Biopharmaceutical Co., LTD, Chongqing, China; Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China; Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China

Source PDF DOI Publisher page
186 days

Field-isolate recombinant tick-borne encephalitis viruses define reporter-stability guidelines for antiviral testing in flaviviruses

AuthorsBenoit Besson; Damien Mouton; Yamina Boukenadel; Theo Nass; Soonju Park; Nakyung Lee; Jianhui Li; David Shum; Redmond Smyth; Stefanie C. Becker; Carine Meignin; Sébastien Pfeffer

AffiliationsUniversité de Strasbourg, Architecture et Réactivité de l’ARN, Institut de Biologie Moléculaire et Cellulaire du CNRS, Strasbourg, France; Université de Strasbourg, M3i UPR9022, Institut de Biologie Moléculaire et Cellulaire du CNRS, France; Screening Platform Laboratory, Institut Pasteur Korea, Seongnam, South Korea; Research Group for Vector-Associated Biodiversity and Infection, University of Veterinary Medicine Hanover, Germany; Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hanover, Germany

Source PDF DOI Publisher page
181 days

Class I capsid assembly modulators induce potent anti-HBV activity through direct viral suppression, innate immune activation and caspase-3-independent clearance of infected hepatocytes

AuthorsPu Wang; Xinchang Liu; Yong Xie; Yingjun Zhang; Baohua Gu; Jing Li; Yunfu Chen

AffiliationsSunshine Lake Pharma Co., Ltd., Dongguan, PR China; State Key Laboratory of Anti-Infective Drug Discovery and Development, Dongguan, PR China; Enterprise Key Laboratory of Anti-viral Drug Development for Guangdong Province, Dongguan, PR China

Source PDF DOI Publisher page
74 days

Dihydroartemisinin inhibits Epstein-Barr virus reactivation and replication targeting lytic proteins: insights for drug repurposing

AuthorsHiteshi Vaidya; Manoj Kumar

AffiliationsVirology Unit, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39A, Chandigarh, 160036, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India; Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research (NIPER), Sahibzada Ajit Singh Nagar, Punjab, 160062, India

Source PDF DOI Publisher page
115 days

Dual-targeting engineered binding proteins block SARS-CoV-2 infection and complement activation

AuthorsFan Pu; Yiwan Guo; Xinni Pan; Xin Liu; Fan Yang

AffiliationsDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue #1277, Wuhan, 430022, China; Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine, Wuhan, 430022, China; Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China; Department of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan, 430071, China; Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, Wuhan University, Wuhan, China

Source PDF DOI Publisher page
110 days

HBVZ10 exhibits robust in vivo potency and synergizes with entecavir to drive efficient cccDNA elimination and HBsAg seroclearance

AuthorsBai-Hua Zhang; Yuanping Zhou; Yukun Wu; Stephen Horrigan; Laura Luckenbaugh; Jianming Hu; Fabien Zoulim; Yong-Yuan Zhang

AffiliationsVirology, HBVtech, Rockville, MD, USA; Department of Infectious Diseases & Gastroenterology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China; The YW Statistical Consulting, Ellicott City, MD, USA; Preclinical Department, Noble Life Sciences, Sykesville, MD, USA; Department of Microbiology and Immunology, Penn State College of Medicine, Hershey, PA, USA; UMR PaThLiv U1350, INSERM, Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Lyon Hepatology Institute, IHU EVEREST, Lyon, France

Source PDF DOI Publisher page
137 days

Oligomerized receptor binding domain blocks pan-sarbecovirus infection via enhanced avidity to host receptor

AuthorsJintao Zou; Lingyu Su; Jiansheng Lu; Haiming Jing; Jiahang Liu; Xiaoqiang Zeng; Menghan Ma; De Zhao; Jun Zhang; Zhang Zhang; Jinyong Zhang; Xiaopeng Zhang

AffiliationsNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, 100071, China; Nanhu Laboratory, Jiaxing, Zhejiang, 314050, China; National Engineering Research Center of Immunological Products, Department of Microbiology and Biochemical Pharmacy, College of Pharmacy and Laboratory Medicine, Army Medical University, Chongqing, 400038, China

Source PDF DOI Publisher page
26 days

Antiviral profile of hepatitis B virus capsid assembly modulator ALG-001075, the parent of pevifoscorvir sodium

AuthorsYannick Debing; Hannah Vanrusselt; Cheng Liu; Jordi Verheyen; Lars Degrauwe; Dieudonné Buh Kum; Abel Acosta Sanchez; Adilson Carlos Francisco; Emma Wanicek; Hans J. Netter; Paul A. Ramsland; Andrew Leis; Shabih Shakeel; Jerome Deval; Michael Welch; Vladimir Serebryany; Antitsa Stoycheva; Leonid Beigelman; Pierre Raboisson; Sandrine Vendeville; Tse-I Lin; Lawrence M. Blatt; David B. Smith; Julian A. Symons; Lauriane Lecoq; Andreas Jekle

AffiliationsAligos Belgium BV, Leuven, Belgium; Aligos Therapeutics, Inc., South San Francisco, United States; Novalix, Leuven, Belgium; Molecular Microbiology and Structural Biochemistry (MMSB), UMR 5086 CNRS, Université de Lyon, France; School of Science, STEM College, RMIT University, Bundoora, Victoria, Australia; Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia; The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Melbourne, VIC, 3052, Australia; Department of Medical Biology, The University of Melbourne, Parkville, Melbourne, VIC, 3052, Australia; Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, VIC, 3052, Australia; ARC Centre for Cryo-electron Microscopy of Membrane Proteins, Bio21 Molecular Science and 9 Biotechnology Institute, The University of Melbourne, Parkville, Melbourne, VIC, 3052, Australia

Source PDF DOI Publisher page
152 days

Antiviral activity of nirmatrelvir against contemporary SARS-CoV-2 variants

AuthorsIrina Yurgelonis; Devendra K. Rai; Jonathan T. Lee; Zhenghui Li; Patricia McMonagle; Qingyi Yang; Weiqiang Li; Li Hao; Hussin A. Rothan; Brittany Washington; Elizabeth Titova; Mohammad Amin Behzadi; Alexey Gribenko; Kris M. White; Barry N. Kreiswirth; Yuao Zhu; Isabel Najera; Elaine Thomas; Rhonda D. Cardin; Charlotte M.N. Allerton; Annaliesa S. Anderson

AffiliationsAnti-Infectives, Pfizer Inc, Pearl River, NY, 10965, USA; Anti-Infectives, Pfizer Inc, Groton, CT, 06340, USA; Vaccines, Pfizer Inc., Pearl River, NY, 10965, USA; Internal Medicine, Pfizer Inc, Cambridge, MA, 02139, USA; Department of Microbiology, Icahn School of Medicine at Mt. Sinai, New York, NY, 10029, USA; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 07110, USA; Preclinical & Translational Sciences, Pfizer Inc, Cambridge, MA, 02139, USA; Anti-Infectives, Pfizer Inc, Cambridge, MA, 02139, USA; Internal Medicine, Pfizer Inc., London, UK

Source PDF DOI Publisher page
117 days

Construction of a suckling mouse model based on an EV-C96 clinical isolate and its application in drug screening and vaccine development

AuthorsJing Wang; Ying Qu; Yunyi He; Qiu Yang; Hanyu Zhu; Yongbei Chen; Xianlong Duan; Huanying Zheng; Shengjun Xiao; Qiliang Liu; Hongbo Liu

AffiliationsDepartment of Laboratory Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China; School of Pharmacy, Guilin Medical University, Guilin, Guangxi, China; Guangxi Key Laboratory of Multimodal Biomarkers and Precision Diagnosis, Guilin Medical University, Guilin, Guangxi, China; School of Laboratory Medicine and Biotechnology, Guilin Medical University, Guilin, Guangxi, China; Department of Laboratory Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China; Guangdong Provincial Institute of Public Health, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China; Department of Pathology, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China; Key Laboratory of Medical Biotechnology and Translational Medicine, Education Department of Guangxi Zhuang Autonomous Region, Guilin, Guangxi, China

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.